Head-to-head comparisons of medication uses, side effects, warnings, and more.
Velsipity (etrasimod)
Rinvoq (upadacitinib)
Velsipity (etrasimod)
Rinvoq (upadacitinib)
Summary of Velsipity vs. Rinvoq
Summary for S1P receptor modulator
Prescription only
Velsipity (etrasimod) is a medication that treats ulcerative colitis (UC) in adults. It works as a sphingosine 1-phosphate (S1P) receptor modulator to help relieve gut inflammation and symptoms of UC. The usual dose is 1 tablet by mouth once a day. Velsipity (etrasimod) can cause side effects like headache and dizziness. It also has a few serious risks, including infection, heart problems, and liver damage. Velsipity (etrasimod) is available as a brand-name medication.
Summary for JAK inhibitor
Prescription only
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor. It's used to treat certain inflammatory conditions, such as rheumatoid arthritis (RA), ulcerative colitis (UC), and eczema (atopic dermatitis). But it's not a first-choice option and typically only prescribed when other treatments haven't worked well. Rinvoq (upadacitinib) is taken by mouth, usually once daily. It's available as an extended-release tablet (Rinvoq) and an oral solution (Rinvoq LQ), but the two formulations aren't interchangeable. Side effects include a higher risk of infections, acne, and nausea.